Completed PHASE3 INTERVENTIONAL 2-arm NCT03066804

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients (PARALLAX)

A 24-week, Randomized, Double-blind, Multi-center, Parallel LCZ696 on NT-proBNP, Exercise Capacity, Symptoms and Safety Compared to Individualized Medical Management of Comorbidities in Patients With Heart Failure and Preserved Ejection Fraction

Sponsor: Novartis Pharmaceuticals

Conditions Heart Failure With Preserved Ejection Fraction

Interventions Enalapril Placebo to match enalapril Placebo to match sacubitril/valsartan Placebo to match valsartan Valsartan sacubitril/valsartan

Updated 23 times since 2017 Last updated: Oct 7, 2021 Started: Aug 22, 2017 Primary completion: Oct 28, 2019 Completion: Oct 28, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Heart Failure With Preserved Ejection Fraction and is currently completed. Novartis Pharmaceuticals leads this study, which shows 23 recorded versions since 2017 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

23 versions recorded

Nov 2025 — Present [monthly]

Completed PHASE3
Sep 2025 — Nov 2025 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Nov 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 18 earlier versions

Mar 2021 — Nov 2021 [monthly]

Completed PHASE3
Jan 2021 — Mar 2021 [monthly]

Completed PHASE3
Sep 2020 — Jan 2021 [monthly]

Completed PHASE3
Apr 2020 — Sep 2020 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Sep 2019 — Apr 2020 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Mar 2019 — Sep 2019 [monthly]

Recruiting PHASE3
Jan 2019 — Mar 2019 [monthly]

Recruiting PHASE3
Dec 2018 — Jan 2019 [monthly]

Recruiting PHASE3
Nov 2018 — Dec 2018 [monthly]

Recruiting PHASE3
Oct 2018 — Nov 2018 [monthly]

Recruiting PHASE3
Sep 2018 — Oct 2018 [monthly]

Recruiting PHASE3
Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE3
Mar 2018 — Jun 2018 [monthly]

Recruiting PHASE3
Feb 2018 — Mar 2018 [monthly]

Recruiting PHASE3
Jan 2018 — Feb 2018 [monthly]

Recruiting PHASE3
Dec 2017 — Jan 2018 [monthly]

Recruiting PHASE3
Sep 2017 — Dec 2017 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
May 2017 — Sep 2017 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Abington, United States , Adana, Turkey (Türkiye) , Addlestone, United Kingdom , Ahmedabad, India , Alexandria, United States , Alicante, Spain , Almelo, Netherlands , Amsterdam, Netherlands , Andalusia, United States and 301 more locations